RADX Stock Overview
Engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Radiopharm Theranostics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$4.39 |
| 52 Week High | AU$50.82 |
| 52 Week Low | AU$4.20 |
| Beta | 0.82 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -75.16% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| RADX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.0% | -3.8% | -2.7% |
| 1Y | n/a | -2.6% | 23.4% |
Return vs Industry: Insufficient data to determine how RADX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how RADX performed against the US Market.
Price Volatility
| RADX volatility | |
|---|---|
| RADX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RADX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine RADX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Riccardo Canevari | www.radiopharmtheranostics.com |
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors.
Radiopharm Theranostics Limited Fundamentals Summary
| RADX fundamental statistics | |
|---|---|
| Market cap | US$32.62m |
| Earnings (TTM) | -US$29.99m |
| Revenue (TTM) | US$1.22m |
26.6x
P/S Ratio-1.1x
P/E RatioIs RADX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RADX income statement (TTM) | |
|---|---|
| Revenue | AU$1.96m |
| Cost of Revenue | AU$21.61m |
| Gross Profit | -AU$19.65m |
| Other Expenses | AU$28.30m |
| Earnings | -AU$47.95m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.022 |
| Gross Margin | -1,003.25% |
| Net Profit Margin | -2,448.23% |
| Debt/Equity Ratio | 0% |
How did RADX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 19:06 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Radiopharm Theranostics Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Hunter Diamond | Diamond Equity Research LLC |
| Justin Walsh | JonesTrading Institutional Services, LLC |